Literature DB >> 20562447

Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease.

Hui Liu1, Loubna El Zein, Martin Kruse, Romain Guinamard, Alf Beckmann, André Bozio, Güven Kurtbay, André Mégarbané, Iris Ohmert, Gérard Blaysat, Elisabeth Villain, Olaf Pongs, Patrice Bouvagnet.   

Abstract

BACKGROUND: Isolated cardiac conduction block is a relatively common condition in young and elderly populations. Genetic predisposing factors have long been suspected because of numerous familial case reports. Deciphering genetic predisposing factors of conduction blocks may give a hint at stratifying conduction block carriers in a more efficient way. METHODS AND
RESULTS: One Lebanese family and 2 French families with autosomal dominant isolated cardiac conduction blocks were used for linkage analysis. A maximum combined multipoint lod score of 10.5 was obtained on a genomic interval including more than 300 genes. After screening 12 genes of this interval for mutation, we found a heterozygous missense mutation of the TRPM4 gene in each family (p.Arg164Trp, p.Ala432Thr, and p.Gly844Asp). This gene encodes the TRPM4 channel, a calcium-activated nonselective cation channel of the transient receptor potential melastatin (TRPM) ion channel family. All 3 mutations result in an increased current density. This gain of function is due to an elevated TRPM4 channel density at the cell surface secondary to impaired endocytosis and deregulation of Small Ubiquitin MOdifier conjugation (SUMOylation). Furthermore, we showed by immunohistochemistry that TRPM4 channel signal level is higher in atrial cardiomyocytes than in common ventricular cells, but is highest in Purkinje fibers. Small bundles of highly TRPM4-positive cells were found in the subendocardium and in rare intramural bundles.
CONCLUSIONS: the TRPM4 gene is a causative gene in isolated cardiac conduction disease with mutations resulting in a gain of function and TRPM4 channel being highly expressed in cardiac Purkinje fibers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562447     DOI: 10.1161/CIRCGENETICS.109.930867

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  73 in total

Review 1.  TRPM channels: same ballpark, different players, and different rules in immunogenetics.

Authors:  Ammad Ahmad Farooqi; Mohammed Khalid Javeed; Zeeshan Javed; Asma M Riaz; Shahzeray Mukhtar; Sehrish Minhaj; Sana Abbas; Shahzad Bhatti
Journal:  Immunogenetics       Date:  2011-09-20       Impact factor: 2.846

Review 2.  Emerging concepts for the role of TRP channels in the cardiovascular system.

Authors:  Rudi Vennekens
Journal:  J Physiol       Date:  2010-12-20       Impact factor: 5.182

Review 3.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

Review 4.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

5.  Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle.

Authors:  Christophe Simard; Laurent Sallé; René Rouet; Romain Guinamard
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Basal protein kinase Cδ activity is required for membrane localization and activity of TRPM4 channels in cerebral artery smooth muscle cells.

Authors:  Zarine I Garcia; Allison Bruhl; Albert L Gonzales; Scott Earley
Journal:  Channels (Austin)       Date:  2011-05-01       Impact factor: 2.581

Review 7.  Transient receptor potential channels as therapeutic targets.

Authors:  Magdalene M Moran; Michael Allen McAlexander; Tamás Bíró; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

8.  Next-generation sequencing of 100 candidate genes in young victims of suspected sudden cardiac death with structural abnormalities of the heart.

Authors:  C L Hertz; S L Christiansen; L Ferrero-Miliani; M Dahl; P E Weeke; G L Ottesen; R Frank-Hansen; H Bundgaard; N Morling
Journal:  Int J Legal Med       Date:  2015-09-17       Impact factor: 2.686

Review 9.  The TRPM4 channel inhibitor 9-phenanthrol.

Authors:  R Guinamard; T Hof; C A Del Negro
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  TRPM4 inhibition promotes angiogenesis after ischemic stroke.

Authors:  Kok Poh Loh; Gandi Ng; Chye Yun Yu; Chee Kong Fhu; Dejie Yu; Rudi Vennekens; Bernd Nilius; Tuck Wah Soong; Ping Liao
Journal:  Pflugers Arch       Date:  2013-09-17       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.